



180C

10-9-92
J. McGee
11-19-92

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Philip C. Comp

Serial No.: 07/919,219

Art Unit: 1806

Filed: July 24, 1992

Examiner: D. Lacey

For: BLOCKADE OF PROTEIN C ACTIVATION REDUCES
MICROVASCULAR SURGICAL BLOOD LOSS

Commissioner of Patents
and Trademarks
Washington D.C. 20231

GROUP 1806

AMENDMENT AND RESPONSE TO NOTICE TO COMPLY WITH
REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES AND
DECLARATION UNDER 37 C.F.R. §1.821(f)

Sir:

Applicants enclose a copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed September 29, 1992 in the above-identified application.

Applicants enclose substitute pages, numbered 22 and 23, and request that pages 22 through 24, as filed in the original application, be renumbered as pages 24 through 26. Applicants also enclose an appropriately labelled diskette containing the nucleotide sequences.

IN THE SPECIFICATION

Page 12, line 21, after "(EDQVDPRLIDGK)" insert --
(Sequence ID No. 1) --.

I declare that the material on the enclosed diskette is identical in substance to the sequences which were filed with the

U.S.S.N. 07/919,219

Filed: July 24, 1992

AMENDMENT AND RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE
AND/OR AMINO ACID SEQUENCE DISCLOSURES AND
DECLARATION UNDER 37 CFR §1.821(f)

application on July 15, 1991, as well as that enclosed herein,
and that all statements made on information and belief are
believed to be true and further that these statements were made
with the knowledge that willful false statements may jeopardize
the validity of the application or any patent issuing thereon.

Respectfully submitted,




Patrea L. Pabst
Reg. No. 31, 284

Date: October 20, 1992
KILPATRICK & CODY
1100 Peachtree Street
Suite 2800
Atlanta, Georgia 30309-4530
(404) 815-6508

CERTIFICATE OF MAILING (37 C.F.R. 1.8a)

I hereby certify that this Response to Notice to Comply
with Requirements for Patent Applications Containing Nucleotide
Sequence and/or Amino Acid Sequence Disclosures and Declaration
under 37 C.F.R. §1.821(f), along with any paper referred to as
being attached or enclosed, is being deposited with the United
States Postal Service on the date shown below with sufficient
postage as first-class mail in an envelope addressed to the
Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Date: October 20, 1992



Patrea L. Pabst

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR § 1.821(a)(1) and (a)(2). However, this application fails to comply with one or more of the requirements of 37 CFR §§ 1.821 through 1.825 as follows:

- ☒ 1. This application clearly fails to comply with the collective requirements of §§ 1.821 through 1.825. Applicant's attention is directed to these regulations, a copy of which is attached. *See the sequence on page 13 line 24*
- ☐ 2. This application does not conform exclusively to the requirements of §§ 1.821 through 1.825. The non-conforming material should be deleted. § 1.821(b).
- ☐ 3. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing." § 1.821(c).
- ☐ 4. This application does contain, as a separate part of the disclosure on paper copy, a "Sequence Listing." However, the "Sequence Listing" does not comply with the requirements of §§ 1.821 through 1.825 as follows:
- ☐ a. The sequence data does not comply with the symbol and format requirements of paragraphs (b) through (p) of § 1.822. Specifically: _____
- ☐ b. The "Sequence Listing" does not comply with the location and page requirements of paragraph (a) of § 1.823.
- ☐ c. The "Sequence Listing" does not comply with the information requirements of paragraph (b) of § 1.823. Specifically: _____
- ☐ d. Other: _____
- ☐ 5. The description and/or claims of the patent application mention a sequence that is set forth in the "Sequence Listing" but reference is not properly made to the sequence by use of a sequence identifier as required by § 1.821(d).
- ☐ 6. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by § 1.821(e).
- ☐ 7. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the computer readable form does not comply with the requirements of § 1.824. Specifically: _____
- ☐ 8. A statement that the content of the paper and computer readable copies are the same has not been submitted as required by § 1.821(f).
- ☐ 9. The amendment to or replacement of the paper and/or computer readable copies of the "Sequence Listing" does not comply with the requirements of § 1.825(a) through (c).
- ☐ 10. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable. Applicant must provide a substitute copy of the data in computer readable form accompanied by a statement that the substitute data is identical to that originally filed. § 1.825(d). Specifically: _____
- ☐ 11. Other: _____

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE ABOVE REQUIREMENTS. Failure to comply with the above requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR § 1.136. Direct the response to, and any questions about, this notice to the undersigned. A copy of this notice MUST be returned with your response.

☐ _____
For: Manager, Application Processing Division
(703) 308-1202 or 308- _____

☒ Ron Schwadron
Examining Group 1806
(703) 308- _____